EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Population pharmacokinetic modeling of abacavir in HIV-exposed neonates and children with HIV-1 using data from the IMPAACT 2019 and PETITE studies

Won-Ho Kang iD, Yu-Wei Lin iD, Hardik Chandasana iD, Jon Collins iD, Adrie Bekker iD, Tim R Cressey, Kristina M Brooks iD, Isabelle Deprez, S Y Amy Cheung, Mark Bush iD, Rashmi Mehta iD, IMPAACT 2019 Team and PETITE Team

Antimicrobial Agents and Chemotherapy · 03.11.2026

DOI: 10.1128/aac.00702-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, online erschienen am 03.11.2026. Verfasst von Won-Ho Kang und 11 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Durham, North Carolina, USA. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Abacavir (ABC) is one of the primary HIV nucleoside reverse transcriptase inhibitors used in pediatric antiretroviral therapy, yet optimal dosing in neonates and infants is challenging because of rapid developmental changes that influence its pharmacokinetics (PK). In this work, a previously developed pediatric population pharmacokinetic (PopPK) model for ABC was refined to extend its applicability to neonates and young infants by incorporating maturation-related processes and newly available clinical data. PK data from the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) 2019 and PETITE studies, which included term neonates (

Schlagwörter

Stichwörter der Autor:innen

HIVabacavirmodel-informed drug developmentpediatricspharmacometricspopulation pharmacokinetics model

Autor:innen und Institutionen

  • GSK, Durham, North Carolina, USA.
  • Certara, Radnor, Pennsylvania, USA.
  • ViiV Healthcare, Durham, North Carolina, USA.
  • Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa.
  • AMS-PHPT Research Collaboration, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand.
  • Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom.

ORCID-Profile: Won-Ho Kang, Yu-Wei Lin, Hardik Chandasana, Jon Collins, Adrie Bekker, Kristina M Brooks, Mark Bush, Rashmi Mehta

Zitieren

APA

Kang, W., Lin, Y. W., Chandasana, H., Collins, J., Bekker, A., R Cressey, T., Brooks, K. M., Deprez, I., Cheung, S. Y. A., Bush, M., Mehta, R., & IMPAACT 2019 Team and PETITE Team (2026). Population pharmacokinetic modeling of abacavir in HIV-exposed neonates and children with HIV-1 using data from the IMPAACT 2019 and PETITE studies. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00702-26

Vancouver

Kang W, Lin YW, Chandasana H, Collins J, Bekker A, R Cressey T, et al. Population pharmacokinetic modeling of abacavir in HIV-exposed neonates and children with HIV-1 using data from the IMPAACT 2019 and PETITE studies. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.00702-26

BibTeX
@article{Kang2026,
  author = {Kang, Won-Ho and Lin, Yu-Wei and Chandasana, Hardik and Collins, Jon and Bekker, Adrie and R Cressey, Tim and Brooks, Kristina M and Deprez, Isabelle and Cheung, S Y Amy and Bush, Mark and Mehta, Rashmi and IMPAACT 2019 Team and PETITE Team, IMPAACT 2019 Team and PETITE Team},
  title = {Population pharmacokinetic modeling of abacavir in HIV-exposed neonates and children with HIV-1 using data from the IMPAACT 2019 and PETITE studies},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  doi = {10.1128/aac.00702-26}
}
Kostenlos starten →